Loading…
AEON Biopharma, Inc. is projected to decline to $0.6463 by 2027, a -14% move from its current price of $0.75. AEON is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.7164 | $0.7495 | $0.7841 | -0.07% |
| May 30 | $0.7027 | $0.749 | $0.7984 | -0.13% |
| May 31 | $0.6922 | $0.7485 | $0.8094 | -0.20% |
| Jun 1 | $0.6834 | $0.748 | $0.8187 | -0.26% |
| Jun 2 | $0.6758 | $0.7475 | $0.8269 | -0.33% |
| Jun 3 | $0.6688 | $0.747 | $0.8344 | -0.40% |
| Jun 4 | $0.6625 | $0.7465 | $0.8412 | -0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6625 | $0.7465 | $0.8412 | -0.46% |
| Week 2 | $0.6276 | $0.7431 | $0.8798 | -0.92% |
| Week 3 | $0.6014 | $0.7396 | $0.9096 | -1.38% |
| Week 4 | $0.5798 | $0.7362 | $0.9348 | -1.84% |
| Week 5 | $0.5611 | $0.7328 | $0.9571 | -2.29% |
| Week 6 | $0.5444 | $0.7294 | $0.9773 | -2.75% |
| Week 7 | $0.5293 | $0.726 | $0.9958 | -3.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AEON Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
AEON Biopharma operates in the Healthcare sector, pursuing clinical development programs and collaborations to advance its botulinum toxin programs."
AEON Biopharma, Inc. (AEON) is a Healthcare sector company trading under the symbol AEON. The current price is $0.7772, with a market capitalization of $20.45M and a rank of 4933.
The near-term price environment is reflected in the latest technicals: sentiment is NEUTRAL, RSI(14) is 40, and the moving averages sit at SMA50 $0.9612 and SMA200 $0.9537. Support sits at $0.722 and resistance at $1.09, with a 30-day range of $0.5669 to $1.07.
The forecast implies a cautious start in 2026 with a min of $0.722, an avg of $0.7772, and a max of $1.03, yielding a 0% ROI and NEUTRAL sentiment. The data provide year-by-year paths showing varying upside and downside potential, culminating in notable longer-term bullishness in several years.
A major floor 35.2% below — a decisive break under it would weaken the trend.
The nearest floor, 3.7% below — buyers have tended to step in here.
The nearest ceiling, 45.3% above — a clean break opens room to run.
A major ceiling 81.3% above — clearing it would confirm fresh momentum.
Key AEON support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AEON market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7962 | Sell | $0.7838 | Sell |
| MA 10 | $0.8034 | Sell | $0.8104 | Sell |
| MA 20 | $0.8577 | Sell | $0.8525 | Sell |
| MA 50 | $0.9466 | Sell | $0.9274 | Sell |
| MA 100 | $1.04 | Sell | $1.04 | Sell |
| MA 200 | $0.9543 | Sell | $6.04 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.59 | Neutral |
| Stoch RSI (14) | 47.55 | Neutral |
| CCI (20) | -130.90 | Sell |
| Williams %R (14) | -85.11 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -16.67 | Sell |
| Bollinger %B (20,2) | 0.09 | Neutral |
| Stochastic %K (14) | 14.89 | Buy |
| TRIX (15) | -0.69 | Sell |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 46.20 | Neutral |
| Momentum (10) | -0.13 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 0.76 | Sell |
| ADX (14) | 19.28 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is NEUTRAL overall. RSI(14) is 40, indicating neither overbought nor oversold conditions in the near term.
SMA50 is $0.9612 and SMA200 is $0.9537, offering a near-term crossroad around the current price. Support is at $0.722 and resistance at $1.09, framing the immediate trading band. The 30-day price range spans from $0.5669 to $1.07, illustrating recent volatility within that window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.722 | $0.75 | $0.9873 | 0% | Neutral | |
| $0.4801 | $0.6463 | $0.9375 | -14% | Neutral | |
| $0.589 | $0.8322 | $1.27 | +11% | Neutral | |
| $0.6336 | $0.933 | $1.49 | +24% | Bullish | |
| $0.5972 | $0.9128 | $1.51 | +22% | Bullish | |
| $0.6226 | $0.9853 | $1.68 | +31% | Bullish | |
| $0.516 | $0.8438 | $1.48 | +13% | Neutral | |
| $0.4598 | $0.7759 | $1.39 | +3% | Neutral | |
| $0.5504 | $0.9573 | $1.76 | +28% | Bullish | |
| $0.6508 | $1.17 | $2.18 | +55% | Bullish | |
| $0.5588 | $1.15 | $2.35 | +53% | Bullish | |
| $1.04 | $2.30 | $5.30 | +207% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.722 | $0.75 | $0.8814 | +0.00% |
| June 2026 | $0.5881 | $0.7006 | $0.8617 | -6.58% |
| July 2026 | $0.5843 | $0.706 | $0.8873 | +0.76% |
| August 2026 | $0.5898 | $0.7206 | $0.9208 | +2.08% |
| September 2026 | $0.5543 | $0.6835 | $0.8851 | -5.16% |
| October 2026 | $0.537 | $0.6678 | $0.8753 | -2.29% |
| November 2026 | $0.5708 | $0.7152 | $0.9472 | +7.09% |
| December 2026 | $0.5848 | $0.7381 | $0.9873 | +3.20% |
Click any year to see its month-by-month AEON forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, AEON is projected to trade between $0.722 and $0.9873, averaging $0.75 — a potential gain of 0% from today's $0.75. Price action looks broadly range-bound.
AEON Biopharma, Inc.'s 2027 outlook centres on $0.6463, within a $0.4801 to $0.9375 range. That is -14% versus the projected 2026 average. That marks a -14% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, AEON could reach as high as $1.27, with a base case around $0.8322 and support toward $0.589 — roughly +11% from $0.75. Price action looks broadly range-bound.
Expect AEON to range from $0.6336 to $1.49 through 2029. The $0.933 average target implies a +24% move from current prices. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The AEON price prediction for 2030 points to an average of $0.9128 (low $0.5972, high $1.51) — a potential gain of +22% on today's $0.75. Momentum favours further upside here.
In 2031, AEON is projected to trade between $0.6226 and $1.68, averaging $0.9853 — a potential gain of +31% from today's $0.75. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
AEON Biopharma, Inc.'s 2032 outlook centres on $0.8438, within a $0.516 to $1.48 range. That is -14% versus the projected 2031 average. That marks a +13% change versus current levels. Price action looks broadly range-bound.
By 2033, AEON could reach as high as $1.39, with a base case around $0.7759 and support toward $0.4598 — roughly +3% from $0.75. A consolidation phase looks the most probable path here.
Expect AEON to range from $0.5504 to $1.76 through 2034. The $0.9573 average target implies a +28% move from current prices. That is up +23% on the projected 2033 average. Momentum favours further upside here.
The AEON price prediction for 2035 points to an average of $1.17 (low $0.6508, high $2.18) — a potential gain of +55% on today's $0.75. Buyers look set to stay in control over this stretch.
In 2040, AEON is projected to trade between $0.5588 and $2.35, averaging $1.15 — a potential gain of +53% from today's $0.75. That is -1% versus the projected 2035 average. Momentum favours further upside here.
AEON Biopharma, Inc.'s 2050 outlook centres on $2.30, within a $1.04 to $5.30 range. That is up +100% on the projected 2040 average. That marks a +207% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in AEON today (≈ 1,333.333333 AEON) could be worth
$3,070.43
+$2,070.43 (+207%) by 2050 · US Dollar
Based on the average projected AEON price of $2.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AEONwould be worth at today's price.
$1,000 invested in AEON on May 27, 2025 (≈ 1,647.446476 AEON) would be worth
$1,235.58
+$235.58 (+23.6%) today · 1.24× · US Dollar
Based on a AEON entry price of $0.607 vs. today's $0.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.863 | $869.06 | -13.1% |
| 1 month ago | $1.04 | $721.15 | -27.9% |
| 3 months ago | $1.09 | $688.07 | -31.2% |
| 6 months ago | $0.847 | $885.48 | -11.5% |
| 1 year ago | $0.607 | $1,235.58 | +23.6% |
| All time (3.4y) ago | $724.32 | $1.04 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AEON forecast.
Our base-case forecast reaches $1.50 around 2050.
Implied market cap at $1.50: $39.46M
The multi-year forecast shows a bullish tilt emerging in several later years. For 2029, the avg is $0.9776 with a max of $1.59 and a min of $0.6523, yielding a 25.8% ROI and a BULLISH sentiment.
In 2030, the avg is $0.952 with a max of $1.60 and a min of $0.6102, yielding a 22.5% ROI and a BULLISH sentiment. The 2031 forecast shows avg $1.04, min $0.6402, max $1.80, with a 33.4% ROI and BULLISH sentiment.
Further years show a mix of outcomes, including 2032 with ROI 10.7% and 2033 with ROI 2.2%, while 2034 posts ROI 31.5% and sentiment BULLISH and 2035 with ROI 57.3% and sentiment BULLISH. The longer horizon remains positive, with 2040 at avg $1.21 and ROI 55.7%, and 2050 at avg $2.38 with ROI 206.7%; both years carry BULLISH sentiment.
Tap a question to reveal the answer.
Min $0.722, Avg $0.7772, Max $1.03; ROI 0%; Sentiment NEUTRAL.
Forecasts include multiple bullish years (e.g., 2029 Avg $0.9776, ROI 25.8; 2030 Avg $0.952, ROI 22.5; 2031 Avg $1.04, ROI 33.4; 2034 Avg $1.02, ROI 31.5; 2035 Avg $1.22, ROI 57.3; 2040 Avg $1.21, ROI 55.7; 2050 Avg $2.38, ROI 206.7) alongside a negative year (2027 ROI -14.5). These are estimates and not guarantees. (Investment suitability depends on many factors beyond these numbers.)
Yes. The forecast shows a 2050 max of $5.48, with an average of $2.38 and a ROI of 206.7%; sentiment is BULLISH.
Current price is $0.7772 and market cap is $20.45M. The rank is 4933.
Min $0.6402, Avg $1.04, Max $1.80; ROI 33.4%; Sentiment BULLISH.
AEON Biopharma, Inc. Community Discussion
0Share your AEON Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.